Ftse Mib
33.739,42
0,33%
DAX
18.022,71
0,16%
S&P 500
5.127,79
1,26%
NASDAQ
16.156,33
1,99%
Bitcoin
64.526,87
0,82%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Inhibrx Inc (INBX) Inhibrx Inc (INBX) Notizie

Inhibrx Inc

INBX
34,15
0,00 (0,00%)
06 Mag 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
11/3/202421:26EDGAR2Form 144 - Report of proposed sale of securities
08/3/202422:08EDGAR2Form 144 - Report of proposed sale of securities
08/3/202421:28EDGAR2Form 144 - Report of proposed sale of securities
06/3/202422:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202420:58EDGAR2Form 144 - Report of proposed sale of securities
05/3/202400:26EDGAR2Form 144 - Report of proposed sale of securities
29/2/202423:26EDGAR2Form PREM14A - Preliminary proxy statements relating to..
28/2/202415:15PRNUSInhibrx Reports Fourth Quarter and Fiscal Year 2023..
28/2/202415:12EDGAR2Form 8-K - Current report
28/2/202415:10EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
14/2/202422:12EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
06/2/202422:30EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
26/1/202418:12PRNUSKuehn Law Encourages DOC, BATL, KAMN, and INBX Investors to..
23/1/202423:25EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
23/1/202412:38EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
23/1/202412:35EDGAR2Form 8-K - Current report
23/1/202412:05DJNSanofi to Buy Assets From Inhibrx in Deal Valued at Up to..
23/1/202411:40IHMARKETNEWSWall Street Highlights: Vroom Shuts Down Online Car Sales,..
23/1/202407:00PRNUSInhibrx Announces Sale of INBRX-101 to Sanofi for an..
09/11/202322:03EDGAR2Form 8-K - Current report
09/11/202322:01EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/11/202322:00PRNUSInhibrx Reports Third Quarter 2023 Financial Results and..
02/11/202314:16EDGAR2Form 8-K - Current report
02/11/202314:15PRNUSInhibrx Announces Preliminary Data from the Phase 1 Trial of..
18/10/202322:00PRNUSInhibrx Announces Participation in Upcoming Scientific..
19/9/202322:03EDGAR2Form 8-K - Current report
19/9/202322:00PRNUSInhibrx Retains Rights to INBRX-101 for the Treatment of..
31/8/202322:06EDGAR2Form D - Notice of Exempt Offering of Securities
29/8/202315:03EDGAR2Form 8-K - Current report
29/8/202315:00PRNUSInhibrx Announces $200 Million Private Placement Financing
07/8/202322:03EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/8/202322:00PRNUSInhibrx Reports Second Quarter 2023 Financial Results and..
30/5/202315:46DJNInhibrx Granted FDA Fast Track Designation for INBRX-101
30/5/202315:00PRNUSInhibrx Granted Fast Track Designation for INBRX-101 for the..
08/5/202322:05PRNUSInhibrx Reports First Quarter 2023 Financial Results and..
Apertura: Min: Max:
Chiusura: 34,15

La tua Cronologia

NASDAQ
INBX
Inhibrx
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network